info@strategicmarketresearch.com
92, An Guha Lane, Arya Samaj Gali, Sambalpur, Odisha -768001
Indian Flag  IN: +91-826-083-6500
Home » therapeutics

therapeutics

Arteriovenous Fistula Treatment Market By Treatment Type (Surgical AVF Creation, Percutaneous AVF Creation); By Surgical Method (End-to-End Anastomosis, Side-to-Side Anastomosis); By End User (Hospitals & Dialysis Centers, Outpatient Surgery Centers, Dialysis Clinics, Academic & Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Arteriovenous Fistula (AVF) Treatment Market will experience significant growth during the forecast period from 2024 to 2030 , with a projected CAGR of 8.4Read More

Published Date: NOV-2025 | No Of Pages:194 | $ 4485

Hereditary Angioedema (HAE) Therapeutics Market By Treatment Type (On-Demand, Prophylactic); By Route of Administration (Injectable, Oral); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Hereditary Angioedema (HAE) Therapeutics Market is expanding at a 8.6% CAGR, expected to reach $5.2 billion by 2030 from $2.9 billion in 2024, fueled by <... Read More

Published Date: NOV-2025 | No Of Pages:199 | $ 4485

Aspergillosis Treatment Market By Disease Type (Invasive Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis); By Treatment Type (Triazole Antifungals, Polyenes, Echinocandins and Combination/Salvage Therapy, Corticosteroid-Based ABPA Therapy, Emerging Antifungal Therapies); By End User (Hospitals, Transplant and Oncology Centers, Pulmonary and Respiratory Specialty Clinics, Infectious Disease Specialty Clinics); By Region, Segment Revenue Estimation, Forecast, 2026–2032

Aspergillosis Treatment Market: Resistance, Hospital Risk, and Faster Diagnosis Reshape Antifungal Demand

The Global Aspergillosis Treatment Market was valued at USD 4.3 billion in 2025 and is projected to reach USD 6.17 billion by 2032, growing at a CAGR of 5.27%, ac... Read More

Published Date: JUL-2026 | No Of Pages:160 | $ 4485

Personalized Cancer Vaccines Market By Vaccine Type (Neoantigen-Based, Dendritic Cell, RNA-Based); By Cancer Type (Melanoma, Lung Cancer, Glioblastoma, Colorectal Cancer, Others); By End User (Academic & Research Institutes, Hospitals & Cancer Centers, Biotechnology & Pharma Companies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Personalized Cancer Vaccines Market is projected to grow from $3.2 billion in 2024 to $9.5 billion by 2030 at a strong 19.8% CAGR, driven by advances in n... Read More

Published Date: NOV-2025 | No Of Pages:166 | $ 4485

Narcolepsy Therapeutics Market By Product Type (CNS Stimulants, Sodium Oxybate-Based Therapies, Selective Histamine H3 Receptor Antagonists/Inverse Agonists, Orexin Receptor Agonists); By Type (Type 1 Narcolepsy, Type 2 Narcolepsy); By Route of Administration (Oral, Oral Liquid, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Narcolepsy Therapeutics Market: Branded Sleep Franchises Face an Orexin-Led Competitive Reset

The Global Narcolepsy Therapeutics Market is estimated to reach USD 3.36 billion in 2025 and is projected to grow to USD 5.91 billio... Read More

Published Date: JUL-2026 | No Of Pages:196 | $ 4485

Gaucher Disease Drugs Market By Product Type (Enzyme Replacement Therapy [ERT], Substrate Reduction Therapy [SRT], Gene Therapy, Other Therapies); By Treatment Type (Pharmacological Treatments, Gene Therapy); By Distribution Channel (Hospital Pharmacies, Specialty Clinics, Online Pharmacies, Research Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Gaucher Disease Drugs Market will witness a robust CAGR of 8.82 % , valued at USD 2.9 billion in 2024 , and is expected to appreciate and r... Read More

Published Date: OCT-2025 | No Of Pages:184 | $ 4485

Pigmentation Disorder Treatment Market By Product Type (Topical Products, Oral Medications, Injectable Treatments, Laser and Light Therapy); By Treatment Method (Pharmacological Treatments, Cosmetic Procedures, Light-based Treatments); By End User (Clinics and Dermatology Centers, Aesthetic Clinics, Home Care); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Pigmentation Disorder Treatment Market will see significant growth from 2024 to 2030, expanding at a robust CAGR of 7.5% to reach USD 8.5 billion by 2030 from USD ... Read More

Published Date: OCT-2025 | No Of Pages:161 | $ 4485

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market By Therapeutic Approach (First-Line, Second-Line, Other Treatments); By Drug Type (Biologics, Oral Therapies, IVIG & Steroids); By Route of Administration (Injectables, Oral Medications); By Region (North America, Europe, Asia Pacific, LAMEA), Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market will expand from $1.3 billion in 2024 to $2.1 billion by 2030, registering a 8.2% CAGR suppo... Read More

Published Date: OCT-2025 | No Of Pages:180 | $ 4485

Mouth Ulcer Treatment Market By Product Type (Corticosteroids, Antihistamines, Analgesics & Anesthetics, Antimicrobial Mouthwashes & Rinses, Nutritional Supplements, Natural & Herbal Products); By Route of Administration (Topical, Oral Systemic); By Distribution Channel (Retail Pharmacies & Drug Stores, Hospital Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Mouth Ulcer Treatment Market will expand at a steady CAGR of 5.6%, increasing from $1.8 billion in 2024 to nearly $2.5 billion by 2030, supported by growt... Read More

Published Date: OCT-2025 | No Of Pages:199 | $ 4485

Critical Limb Ischemia Treatment Market By Treatment Approach (Endovascular Revascularization, Surgical Bypass, Hybrid Revascularization, Deep Vein Arterialization, Wound Care & Limb Preservation Therapy); By Product/Device Type (Drug-Coated Balloons, Stents & Drug-Eluting Scaffolds, Specialty Balloons, Atherectomy Systems, Venous Arterialization Systems, Bypass Grafts, Below-the-Knee Revascularization Devices, Limb-Salvage Systems); By Application (Below-the-Knee Arterial Disease, No-Option CLTI, Diabetic Foot Ulcers, Non-Healing Ischemic Wounds, Rest Pain Management, Gangrene & Tissue Loss, Major Amputation Prevention); By End User (Hospitals, Vascular Centers, Specialty Clinics, Ambulatory Surgical Centers, Wound Care Centers); By Region, Segment Revenue Estimation, Forecast, 2026–2032

Critical Limb Ischemia Treatment Market: Below-the-Knee Devices, Limb-Salvage Systems, and Revascularization Evidence Redefine CLTI Care

The Global Critical Limb Ischemia (CLI) Treatment Market was valued at USD 5.72 billion in 2025 and is projected to reach USD 8.87 ... Read More

Published Date: JUL-2026 | No Of Pages:150 | $ 4485

Autism Spectrum Disorder Treatment Market By Treatment Type (Pharmacological, Behavioral Therapies, Assistive Technologies, Digital Therapeutics, Complementary & Alternative Treatments); By Age Group (Children, Adolescents, Adults); By Distribution Channel (Hospitals & Clinics, Specialty Centers, Online Platforms, Home-Based Care); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Autism Spectrum Disorder (ASD) Treatment Market will witness a robust CAGR of 7.6% , valued at $3.42 billion in 2024Read More

Published Date: OCT-2025 | No Of Pages:186 | $ 4485

Retinal Vein Occlusion Treatment Market By Treatment Type (Anti-VEGF Therapy, Corticosteroid Therapy, Laser Therapy, Investigational & Disease-Modifying Therapies); By Anti-VEGF Molecule Type (Aflibercept, Faricimab, Ranibizumab, Bevacizumab, Biosimilar Anti-VEGF Agents); By Disease Type (Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion); By Treatment Setting (Retina Specialty Centers, Ophthalmology Clinics, Hospitals, Ambulatory Retina Care Settings); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Clinic-Based Procurement, Retail Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Retinal Vein Occlusion Treatment Market: Longer-Interval Anti-VEGF, Biosimilar Pressure, and Real-World Injection Burden Redefine Retina Care

The Global Retinal Vein Occlusion (RVO) Treatment Market was valued at USD 2.57 billion in 2025 and is projected to reach USD ... Read More

Published Date: JUL-2026 | No Of Pages:171 | $ 4485

Primary Biliary Cholangitis (PBC) Market By Drug Type (Ursodeoxycholic Acid, Obeticholic Acid, and Other Drugs); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Region (North America, Europe, Asia Pacific, LAMEA), Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Primary Biliary Cholangitis (PBC) Market will witness a robust CAGR of 8.01 % , valued... Read More

Published Date: OCT-2025 | No Of Pages:174 | $ 4485

Nicotine Replacement Therapy Market By Product Type (Gum, Patch, Inhaler, Nasal Spray, Lozenges); By Route of Administration (Oral, Nasal, Transdermal, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Nicotine Replacement Therapy (NRT) Market will witness a robust CAGR of 6.7%, valued at $3.86 billion in 2024 , expected to appreciate an... Read More

Published Date: OCT-2025 | No Of Pages:163 | $ 4485

Relapsed and Refractory Multiple Myeloma Treatment Market Relapsed and Refractory Multiple Myeloma (RRMM) Treatment Market By Treatment Modality (Immunomodulatory Drugs, Proteasome Inhibitors, Monoclonal Antibodies, CAR-T Cell Therapy, Bispecific Antibodies); By Line of Therapy (Second-Line Therapy, Third-Line and Beyond); By Route of Administration (Oral, Intravenous); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Relapsed And Refractory Multiple Myeloma Treatment Market will witness a robust CAGR of 7.4% , valued at $16.8 billion in 2024Read More

Published Date: OCT-2025 | No Of Pages:160 | $ 4485

Ovarian Cancer Drugs Market By Drug Type (Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs); By Treatment Approach (First-Line Treatment, Second-Line Treatment, Adjuvant Therapy); By Region (North America, Europe, Asia Pacific, LAMEA); Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Ovarian Cancer Drugs Market will witness a robust CAGR of 7.6% , valued at $5.3 billion in 2024 , and is projected to reach $9.2 ... Read More

Published Date: OCT-2025 | No Of Pages:167 | $ 4485

Tuberculosis Therapeutics Market By Drug Class (First-Line Therapy, Second-Line Therapy); By Disease Type (Active TB, Latent TB); By Route of Administration (Oral, Injectable); By Distribution Channel (Public Programs, Hospital Pharmacies, Retail Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Tuberculosis Therapeutics Market will witness a steady CAGR of 6.1% , valued at $1.34 billion in 2024 , and is expected to reach $1.91 billion by 2030 , c... Read More

Published Date: OCT-2025 | No Of Pages:196 | $ 4485

Iron Deficiency Anemia Therapy Market By Therapy Type (Oral Iron Supplements, Intravenous Iron Therapy, Erythropoiesis-Stimulating Agents); By Route of Administration (Oral, Intravenous); By End User (Hospitals, Clinics, Homecare, Specialty Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Iron Deficiency Anemia Therapy Market: Infusion Convenience, Payer Preference and Prescription Oral Innovation Reshape Commercial Value

The Global Iron Deficiency Anemia Therapy Market is estimated to reach USD 5.19 billion in 2025Read More

Published Date: JUL-2026 | No Of Pages:153 | $ 4485

Herpes Simplex Virus Treatment Market by Treatment Type (Antiviral Drugs, Vaccines); By Type of Infection (HSV-1, HSV-2); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Herpes Simplex Virus ( HSV ) Treatment Market is poised for significant growth, expected to grow at a CAGR of 5.7% valued at USD 9.8 billionRead More

Published Date: OCT-2025 | No Of Pages:178 | $ 4485

Substance Abuse Treatment Market By Treatment Type (Medication-Assisted Treatment, Behavioral Therapies & Counseling, Residential/Inpatient Treatment, Outpatient Treatment Programs); By Substance Type (Alcohol Dependence, Opioid Dependence, Cannabis Use Disorder, Cocaine and Stimulant Addiction, Prescription Drug Abuse, Others); By End User (Hospitals, Specialty Rehabilitation Centers, Private Clinics and Individual Practitioners, Government & Community Organizations, Telehealth and Digital Platforms); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Substance Abuse Treatment Market will witness a robust CAGR of 6.8% , valued at $21.3 billion in 2024 , expected to appreciate and reach $31.7 billion by 2030Read More

Published Date: OCT-2025 | No Of Pages:170 | $ 4485

Non-Hodgkin Lymphoma (NHL) Therapeutics Market By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy, Stem Cell Transplantation); By Indication (B-cell NHL, T-cell NHL); By End-User (Hospitals, Oncology Clinics, Research Centers, Outpatient Treatment Centers); By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2024–2030.

Introduction and Strategic Context

The global Non-Hodgkin Lymphoma (NHL) Therapeutics Market is expected to experience robust growth, reaching a market value of $15.2 billion in 2024 and growing to $32.5 billion by 20... Read More

Published Date: OCT-2025 | No Of Pages:178 | $ 4485

Oncolytic Virus Immunotherapy Market By Type of Oncolytic Virus (Genetically Modified Viruses, Wild-Type Viruses); By Platform (Herpes Simplex Virus (HSV), Adenovirus, Vaccinia Virus, Reovirus, Vesicular Stomatitis Virus, Measles Virus, Coxsackievirus, Newcastle Disease Virus); By Application (Cancer Treatment, Combination Therapies); By End-User (Hospitals & Clinics, Research Institutions); By Region (North America, Europe, Asia Pacific, LAMEA), Segment Revenue Estimation, Forecast, 2024–2030

Oncolytic Virus Immunotherapy Market: Engineered Viral Therapy Moves Toward Immune Conversion and Combination Oncology (Last Updated on: June-2026)

The Global Oncolytic Virus Immunotherapy Market is projected to expand at a CAGR of 25.4%, growing from USD 29 mill... Read More

Published Date: OCT-2025 | No Of Pages:182 | $ 4485

Tourette Syndrome Treatment Market Size, Share, and Growth Analysis, By Treatment Modality (Prescription Medicines, Behavioral Therapy, Digital Behavioral Programs, Botulinum Toxin Injections, Deep Brain Stimulation), By Drug Class (Antipsychotics, Alpha-2 Adrenergic Agonists, Dopamine D1 Receptor Antagonists, Adjunctive and Off-Label Medicines), By Patient Age Group (Pediatric Patients, Adult Patients), By Care Setting (Hospitals, Specialty Clinics, Behavioral Therapy Centers, Home-Based and Digital Care), By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Tourette Syndrome Treatment Market: Ecopipam’s Regulatory Advance Opens a Branded Segment in a Generic-Led Treatment Landscape

The Global Tourette Syndrome Treatment Market was valued at USD 2.67 billion in 2025 and is projected to reach USD 3.98 billion by 2032... Read More

Published Date: JUL-2026 | No Of Pages:167 | $ 4485

Retinoblastoma Treatment Market By Treatment Type (Systemic Chemotherapy, Intra-Arterial Chemotherapy, Intravitreal Chemotherapy, Focal Therapy, Radiation Therapy, Surgery); By Disease Presentation (Unilateral Intraocular Disease, Bilateral Intraocular Disease, Extraocular and Metastatic Disease, Recurrent or Refractory Disease); By End User (Specialist Children’s Hospitals, Ocular-Oncology Centers, General Hospitals, Cancer Treatment Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Retinoblastoma Treatment Market: Globe-Salvage Procedures Expand While Enucleation Remains Essential

The Global Retinoblastoma Treatment Market was valued at USD 1.93 billion in 2025 and is projected to reach USD 2.68 billion by 2032, growing at a CAGR of 4.79%, accor... Read More

Published Date: JUL-2026 | No Of Pages:196 | $ 4485

Pseudomonas Aeruginosa Infection Treatment Market By Drug Class (Traditional Antipseudomonal Beta-Lactams, Carbapenems, Fluoroquinolones, Aminoglycosides, Polymyxins, Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations, Siderophore Cephalosporins, Inhaled Antipseudomonal Antibiotics, Pipeline and Other Therapies); By Route of Administration (Intravenous, Inhalation, Oral); By Infection Type (Hospital-Acquired and Ventilator-Associated Pneumonia, Bloodstream Infection, Urinary Tract Infection, Wound and Burn Infection, Chronic Respiratory Infection, Other Complicated Infections); By Resistance Profile (Susceptible Pseudomonas Aeruginosa Infections, Multidrug-Resistant Infections, Carbapenem-Resistant Infections, Difficult-to-Treat-Resistant Infections); By End User (Hospitals and Intensive-Care Units, Hospital Pharmacies, Specialty Respiratory Clinics, Infectious Disease and Stewardship-Led Care Settings, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Pseudomonas Aeruginosa Infection Treatment Market: Hospital Resistance Shifts Spending Toward Reserve Antibiotics

The Global Pseudomonas Aeruginosa Infection Treatment Market was valued at USD 2.26 billion in 2025 and is projected to reach USD 3.22 billion by 2032, gr... Read More

Published Date: JUL-2026 | No Of Pages:200 | $ 4485

Sarcoma Drugs Market By Drug Type (Chemotherapy, Targeted Therapy, Immunotherapy); By Therapeutic Approach (Adjuvant, Neoadjuvant); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Sarcoma Drugs Market is projected to witness a steady growth rate, with an anticipated CAGR of 7.3% from 2024 to 2030. Valued at $2.5 billion in 2024, it ... Read More

Published Date: OCT-2025 | No Of Pages:155 | $ 4485

Malignant Glioma Therapeutics Market By Therapeutic Type (Chemotherapy, Immunotherapy, Targeted Therapy); By Drug Class (Chemotherapeutic Agents, Monoclonal Antibodies, Immunomodulatory Agents); By End User (Hospitals, Specialized Oncology Centers, Research Institutions); By Region (North America, Europe, Asia-Pacific, LAMEA); Segment Revenue Estimation, Forecast, 2026–2032

Malignant Glioma Therapeutics Market: Biomarker Selection, Repeat Treatment and Access Gaps Shape Neuro-Oncology Demand

The Global Malignant Glioma Therapeutics Market is estimated to reach USD 1.63 billion in 2025 and is projected to... Read More

Published Date: JUL-2026 | No Of Pages:197 | $ 4485

Glioblastoma Multiforme Treatment Market By Treatment Modality (Surgical Resection, Radiation Therapy, Chemotherapy, Tumor Treating Fields, Targeted Therapy, Immunotherapy, Local Radiation Therapy); By Delivery Platform (Systemic Therapy, Local/Intratumoral Delivery, Blood-Brain Barrier Delivery Technologies, Convection-Enhanced Delivery, Focused Ultrasound-Mediated Delivery); By Disease Stage (Newly Diagnosed GBM, Recurrent GBM); By Molecular Profile (MGMT-Methylated GBM, MGMT-Unmethylated GBM, IDH-Wildtype GBM, Other Biomarker-Defined GBM); By End User (Hospitals, Neuro-Oncology Centers, Specialty Cancer Centers, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Glioblastoma Multiforme Treatment Market: Survival Ceiling, Device Adherence, and BBB Delivery Push Revenue Beyond Conventional Chemotherapy

The Global Glioblastoma Multiforme (GBM) Treatment Market was valued at USD 3.72 billion in 2025 and is projected to reach USD ... Read More

Published Date: JUL-2026 | No Of Pages:151 | $ 4485

Peripheral T-Cell Lymphoma Treatment Market By Treatment Type (Anthracycline-Based Chemotherapy, CD30-Directed Therapy, Antimetabolite Therapy, Histone Deacetylase Inhibitors, Oral Targeted Therapy, Salvage Combination Regimens, Transplant-Associated Therapy, Other Therapies); By Disease Subtype (Peripheral T-Cell Lymphoma Not Otherwise Specified, Systemic Anaplastic Large Cell Lymphoma, Nodal T-Follicular-Helper and Angioimmunoblastic-Type Lymphoma, Hepatosplenic T-Cell Lymphoma, Other Systemic Peripheral T-Cell Lymphomas); By Line of Therapy (First-Line, Second-Line, Third-Line and Later); By Route of Administration (Intravenous Therapy, Oral Therapy, Combination Therapy); By End User (Hospitals, Specialty Hematology and Oncology Centers, Transplant Centers, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2025–2032

Peripheral T-Cell Lymphoma Treatment Market: Adcetris Revenue, Repeat Therapy and Asian Oral Launches Reshape Competition

The Global Peripheral T-Cell Lymphoma Treatment Market was valued at USD 694.3 million in 2025 and is projected to reach USD 970.3 million by 2032... Read More

Published Date: JUL-2026 | No Of Pages:156 | $ 4485

Graft-versus-Host Disease Treatment Market By Disease Type (Acute Graft-versus-Host Disease, Chronic Graft-versus-Host Disease); By Treatment Modality (Systemic Corticosteroids and Conventional Immunosuppressants, Targeted Oral Therapies, Infused Biologics, Cellular Therapies, Extracorporeal Photopheresis, Other Salvage Therapies); By Line of Therapy (First-Line Treatment, Second-Line Treatment, Third-Line and Later-Line Treatment); By Route of Administration (Oral, Intravenous, Extracorporeal); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Other Institutional Channels); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Graft-versus-Host Disease Treatment Market: Steroid Failure, Chronic Disease Persistence, and Specialist Drug Launches Drive Commercial Demand

The Global Graft-versus-Host Disease Treatment Market was valued at USD 3.17 billion in 2025 and is projected to reach USD 5.... Read More

Published Date: JUL-2026 | No Of Pages:192 | $ 4485

Scleroderma Therapeutics Market By Drug Class (Immunosuppressants, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Others); By Route of Administration (Oral, Parenteral, Topical); By Disease Type (Localized Scleroderma, Systemic Scleroderma, SSc-PAH, Renal Involvement); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Scleroderma Therapeutics Market is expected to appreciate at 6.6% CAGR, expanding from $3.42 billion in 2024 to $5.04 billion by 2030, propelled by Read More

Published Date: OCT-2025 | No Of Pages:172 | $ 4485

Neglected Tropical Disease Treatment Market By Treatment Type (Preventive Chemotherapy, Disease-Specific Pharmacotherapy, Supportive and Morbidity Management Care, Hospital-Based Acute Care, Pediatric and Field-Ready Formulations); By Disease Type (Lymphatic Filariasis, Onchocerciasis, Schistosomiasis, Soil-Transmitted Helminth Infections, Trachoma, Leprosy, Dengue, Chagas Disease, Leishmaniasis, Human African Trypanosomiasis, Rabies, Snakebite Envenoming, Others); By Access Model (Mass Drug Administration, Donation-Backed Access, Public Procurement, Community Health Delivery, Hospital and Referral-Based Treatment, Diagnostics-Linked Treatment Access); By End User (National NTD Programmes, Public Health Agencies, Hospitals and Referral Centers, NGOs and Implementation Partners, Donor Agencies, Community Health Networks); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Neglected Tropical Disease Treatment Market: Mass Drug Administration, Donation-Backed Access, and Human Rights Policy Reframe Global Demand

The Global Neglected Tropical Disease Treatment Market is projected to grow at a CAGR of 5.9%, expanding from USD 3.87 billion ... Read More

Published Date: JUL-2026 | No Of Pages:166 | $ 4485

Hairy Cell Leukemia Market By Treatment Modality (Purine Analogs, Anti-CD20 Monoclonal Antibodies, BRAF Inhibitors, BRAF/MEK Combination Therapy, Other Combination Therapies); By Disease Type (Classic Hairy Cell Leukemia, Variant Hairy Cell Leukemia/Splenic B-Cell Lymphoma-Leukemia with Prominent Nucleoli); By Treatment Line (Frontline Treatment, Relapsed/Refractory Treatment); By Diagnostic Technology (Flow Cytometry, Molecular Testing/BRAF Mutation Testing, Bone Marrow Biopsy & Immunohistochemistry); By End User (Specialty Oncology Centers, Academic & Research Hospitals, Community Hematology Clinics, Molecular & Reference Laboratories); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hairy Cell Leukemia Market: BRAF-Directed Care Expands Value in a Small, Relapsing Patient Population

The Global Hairy Cell Leukemia Market is projected to grow from USD 212.74 million in 2025 to USD 346.79 million by 2032, registering a CAGR of 7.23% during 2026&ndas... Read More

Published Date: JUL-2026 | No Of Pages:180 | $ 4485

NUT Midline Carcinoma Treatment Market By Treatment Approach (Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy, BET Inhibitor-Based Therapy, Immunotherapy, Combination Therapy); By Molecular Testing Approach (NUT Immunohistochemistry, RNA Sequencing, Next-Generation Sequencing, Fusion Partner Identification); By Disease Site (Thoracic Tumors, Head and Neck Tumors, Bone & Soft Tissue Tumors, Other Primary Sites); By End User (Hospitals, Specialty Cancer Centers, Academic & Research Institutes, Rare Tumor Referral Centers); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa); Segment Revenue Estimation, Forecast, 2026–2032

NUT Midline Carcinoma Treatment Market: Fusion Testing, Thoracic Risk, and BET Inhibitor Development Shape an Ultra-Rare Oncology Market

The Global NUT Midline Carcinoma Treatment Market is projected to grow at a CAGR of 14.9%, expanding from USD 25.2 billion in 2025 ... Read More

Published Date: JUL-2026 | No Of Pages:187 | $ 4485

Skeletal Dysplasia Market By Type of Disorder (Achondroplasia, Hypophosphatasia, Osteogenesis Imperfecta, Thanatophoric Dysplasia, Others); By Treatment Modality (Pharmacological Therapy, Surgical Intervention, Gene Therapy, Assistive Devices); By Diagnostic Technique (Radiographic Imaging, Genetic Testing, Prenatal Diagnosis); By End User (Hospitals, Specialized Clinics, Diagnostic Labs, Academic Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Skeletal Dysplasia Market is set to expand at a robust 7.8% CAGR, valued at $2.14 billion in 2024 and expected to reach $3.37 billion by 2030, driven by <... Read More

Published Date: OCT-2025 | No Of Pages:198 | $ 4485

Antisense and RNAi Therapeutics Market By Therapeutic Type (Antisense Oligonucleotides, RNA Interference); By Application (Genetic Disorders, Oncology, Neurodegenerative Diseases, Ophthalmology, Infectious Diseases); By Route of Administration (Intravenous, Subcutaneous, Intrathecal, Others); By End User (Biopharmaceutical Companies, Hospitals, Specialty Clinics, Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Antisense and RNAi Therapeutics Market Expands Beyond Rare Disease as ATTR and Lipid Drugs Build Billion-Dollar Franchises

The Global Antisense and RNAi Therapeutics Market is estimated to reach USD 6.81 billion in 2025 and is project... Read More

Published Date: JUL-2026 | No Of Pages:196 | $ 4485

Acute Lymphocytic Lymphoblastic Leukemia Therapeutics Market Acute Lymphocytic (Lymphoblastic) Leukemia Therapeutics Market By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplantation); By Route of Administration (Oral, Parenteral); By End User (Hospitals, Specialty Oncology Clinics, Academic & Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Acute Lymphocytic (Lymphoblastic) Leukemia Therapeutics Market is expected to advance at CAGR 8.7%, valued $3.5 billion (2024) and set to hit $6.3 billion (2030)Read More

Published Date: OCT-2025 | No Of Pages:175 | $ 4485

Estrogen Receptor Positive (ER+) Breast Cancer Treatment Market By Treatment Type (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Selective Estrogen Receptor Degraders, CDK4/6 Inhibitors, PI3K Inhibitors, AKT Inhibitors, mTOR Inhibitors, Ovarian Function Suppression Therapies, PROTAC Estrogen Receptor Degraders, Chemotherapy, Antibody-Drug Conjugates); By Application (Early-Stage ER-Positive Breast Cancer, Locally Advanced ER-Positive Breast Cancer, Metastatic ER-Positive Breast Cancer, High-Risk Node-Positive Breast Cancer, Endocrine-Resistant Breast Cancer, ESR1-Mutated Breast Cancer, PIK3CA-Mutated Breast Cancer, AKT1- or PTEN-Altered Breast Cancer, Premenopausal ER-Positive Breast Cancer, Postmenopausal ER-Positive Breast Cancer); By End User (Hospitals, Oncology Clinics, Breast Cancer Treatment Centers, Ambulatory Infusion Centers, Specialty Pharmacies, Retail Pharmacies, Diagnostic and Genomic Testing Laboratories); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Estrogen Receptor-Positive Breast Cancer Treatment Market: Adjuvant CDK4/6 Expansion and ESR1-Guided Switching Move Revenue Beyond Generic Endocrine Therapy

The Global Estrogen Receptor Positive (ER+) Breast Cancer Treatment Market was valued at USD 19.... Read More

Published Date: JUL-2026 | No Of Pages:192 | $ 4485

Artemisinin Combination Therapy Market By Drug Combination Type (Artemether-Lumefantrine, Artesunate-Amodiaquine, DHA-Piperaquine, Artesunate-Mefloquine, Others); By Route of Administration (Oral, Parenteral, Rectal Suppositories); By End User (Public Health Systems, Private Hospitals, NGOs, Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Artemisinin Combination Therapy Market shows strong momentum at CAGR 6.8%, moving from $2.42 billion in 2024 to $3.6 billionRead More

Published Date: OCT-2025 | No Of Pages:178 | $ 4485

Periodontal Therapeutics Market By Product Type (Systemic Antibiotics, Local Antibiotic Delivery Agents, Anti-inflammatory Agents, Regenerative Therapeutics, Host Modulation Agents, Others); By Mode of Administration (Oral, Injectable, Topical); By End User (Dental Clinics, Hospitals, Academic & Research Institutions, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Periodontal Therapeutics Market accelerates at CAGR 6.5% with $8.4 billion in 2024 projected to reach $12.26 billion by 2030, driven by <... Read More

Published Date: OCT-2025 | No Of Pages:154 | $ 4485

Fabry Disease Treatment Market By Therapy Type (Agalsidase Beta Enzyme Replacement Therapy, Agalsidase Alfa Enzyme Replacement Therapy, Pegunigalsidase Alfa Enzyme Replacement Therapy, Migalastat Pharmacological Chaperone Therapy); By Route of Administration (Intravenous, Oral); By Distribution and Care Setting (Hospital Pharmacies and Specialist Infusion Centers, Specialty Pharmacies, Home and Community Infusion Providers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Fabry Disease Treatment Market: Diagnosis Conversion, Genotype Eligibility and ERT Contracting Define Commercial Growth

The Global Fabry Disease Treatment Market was valued at USD 2.91 billion in 2025 and is projected to reach USD 5.06 billion by 2032, growing at a CA... Read More

Published Date: JUL-2026 | No Of Pages:182 | $ 4485

Cystic Fibrosis Therapeutics Market By Drug Type (CFTR Modulators, Antibiotics, Mucolytics, Others); By Route of Administration (Oral, Inhalation, Injectables); By End User (Hospitals, Pharmacies, Home Care, Research Institutions); By Region (North America, Europe, Asia Pacific, LAMEA), Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Cystic Fibrosis Therapeutics Market is set to grow at a CAGR of 8.5%, valued at $5.4 billion in 2024 and reaching $8.8 billionRead More

Published Date: OCT-2025 | No Of Pages:169 | $ 4485

Irritable Bowel Syndrome Treatment Market By Product Type (Prescription Drugs, Over-the-Counter Drugs, Probiotics, Digital Therapeutics); By IBS Subtype (IBS-C, IBS-D, IBS-M, IBS-U); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Telehealth Platforms); By End User (Hospitals, Gastroenterology Clinics, ASCs, Self-care); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Irritable Bowel Syndrome (IBS) Treatment Market is set to grow at a strong CAGR of 9.1%, rising from $3.84 billion in 2024 to $6.75 billion by 2030, drive... Read More

Published Date: OCT-2025 | No Of Pages:157 | $ 4485

Attention Deficit Hyperactivity Disorder (ADHD) Market By Drug Type (Stimulants, Non-Stimulants); By Demographic Group (Children and Adolescents, Adults); By Route of Administration (Oral, Transdermal, Others); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Platforms); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Attention Deficit Hyperactivity Disorder (ADHD) Market grows at CAGR 7.5%, rising from $19.4 billion in 2024 to $29.94 billion by 2030, driven by ... Read More

Published Date: OCT-2025 | No Of Pages:159 | $ 4485

Primary Immunodeficiency Market By Disease Type (Antibody Deficiencies, Combined Immunodeficiencies, Phagocytic Cell Disorders, Complement Deficiencies, Others); By Treatment Type (Immunoglobulin Replacement Therapy, Targeted Biologics, Hematopoietic Stem Cell Transplantation, Gene Therapy, Supportive Therapies); By Route of Administration (Intravenous, Subcutaneous, Oral, Others); By End User (Hospitals & Specialty Clinics, Homecare Settings, Research & Academic Institutes, Others); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Primary Immunodeficiency Market is projected to witness a robust CAGR of 7.8%, valued at USD 8.9 billion in 2024, and expected to reach USD 14.0 billion by 2030Read More

Published Date: OCT-2025 | No Of Pages:193 | $ 4485

Thalassemia Market By Type (Alpha Thalassemia, Beta Thalassemia); By Treatment (Blood Transfusion, Iron Chelation Therapy, Gene Therapy, Bone Marrow/Stem Cell Transplantation, Others); By Route of Administration (Oral, Parenteral); By End User (Hospitals, Specialty Clinics, Research & Academic Institutes, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Thalassemia Market is projected to expand at a strong 8.5% CAGR, growing from $1.89 billion in 2024 to $3.03 billion by 2030, powered by gene ther... Read More

Published Date: OCT-2025 | No Of Pages:189 | $ 4485

Pediatric Diabetes Therapeutics Market By Type (Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus); By Therapeutic Modality (Insulin Therapy, Oral Hypoglycemics, Adjunctive Therapies, CGM Systems, Insulin Delivery Devices); By Route of Administration (Injectable, Oral, Transdermal); By End User (Hospitals, Pediatric Specialty Clinics, Homecare Settings, Academic & Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Pediatric Diabetes Therapeutics Market will witness a robust CAGR of 8.5 % , valued at $12.6 billion in 2024Read More

Published Date: OCT-2025 | No Of Pages:197 | $ 4485

Enzyme Replacement Therapy Market By Product Type (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Alglucosidase Alfa, Idursulfase, Others); By Indication (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidoses, Others); By Route of Administration (Intravenous, Subcutaneous); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Enzyme Replacement Therapy Market: Mature Rare-Disease Biologics Market Shaped by Lifelong Treatment Cost and Next-Generation Delivery (Last Updated on: June-2026)

The Global Enzyme Replacement Therapy (ERT) Market rises at CAGR 7.3%, valued&n... Read More

Published Date: OCT-2025 | No Of Pages:188 | $ 4485

Fungal Keratitis Treatment Market By Product Type (Natamycin, Voriconazole, Amphotericin B, Fluconazole, Posaconazole, Other Antifungal Treatments); By Application (Filamentous Fungal Keratitis, Yeast Fungal Keratitis, Mixed and Other Fungal Keratitis, Refractory and Severe Fungal Keratitis); By End User (Hospitals, Specialty Eye Clinics and Corneal Centres, Ambulatory Surgical Centres, Retail and Specialty Pharmacies, Compounding Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Fungal Keratitis Treatment Market: South Asian Case Volume, Natamycin Access Gaps, and Surgical Escalation Shape Revenue

The Global Fungal Keratitis Treatment Market was valued at USD 1.21 billion in 2025 and is projected to reach USD 1.86 billion by 2032, growing at ... Read More

Published Date: JUL-2026 | No Of Pages:195 | $ 4485

Central Nervous System (CNS) Therapeutics Market By Drug Class (Small Molecule Drugs, Biologics and Advanced Therapies); By Indication (Neurodegenerative Diseases, Psychiatric Disorders, Epilepsy and Seizure Disorders, Multiple Sclerosis, Pain Management and Neuropathic Pain); By Route of Administration (Oral, Injectable, Transdermal/Others); By End User (Hospitals & Specialty Clinics, Retail & Online Pharmacies, Research & Academic Institutes, Mental Health Centers, Military & Veteran Health Systems); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Central Nervous System (CNS) Therapeutics Market is on track for a CAGR of 8.6%, valued at USD 138.2 billion in 2024 and projected to reach USD 226.7 billion by 20... Read More

Published Date: OCT-2025 | No Of Pages:164 | $ 4485

Idiopathic Pulmonary Fibrosis Treatment Market By Drug Type (Antifibrotic Agents, Corticosteroids, Immunosuppressants, Others); By Mechanism of Action (TGF-β Inhibition, Tyrosine Kinase Inhibition, Anti-inflammatory Modulation, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Idiopathic Pulmonary Fibrosis Treatment Market will witness a robust CAGR of 7.8% , valued at $3.1 billion in 2024 , expected to appreciate and reach $5.2 billion ... Read More

Published Date: OCT-2025 | No Of Pages:199 | $ 4485

Crohn’s Disease Therapeutics Market By Drug Class (Aminosalicylates, Corticosteroids, Immunomodulators, Biologics, Small Molecule Therapies, Others); By Route of Administration (Oral, Injectable, Intravenous); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Crohn’s Disease Therapeutics Market will witness a robust CAGR of 6.8% , valued at $14.2 billion in 2024 , and is expected to appre... Read More

Published Date: OCT-2025 | No Of Pages:192 | $ 4485

Type 2 Diabetes Mellitus Treatment Market By Therapeutic Class (GLP-1 Receptor Agonists, Dual GIP/GLP-1 Agonists, SGLT2 Inhibitors, Insulin Therapies, DPP-4 Inhibitors, Metformin, Sulfonylureas, Fixed-Dose and Fixed-Ratio Combinations, Others); By Route and Treatment Format (Oral Therapies, Daily Injectable Therapies, Weekly Injectable Therapies, Combination Therapies); By Patient Risk and Treatment Need (Obesity-Associated Type 2 Diabetes, Cardiovascular-Risk Patients, Chronic Kidney Disease and Heart-Failure Patients, Insulin-Treated Type 2 Diabetes, Newly Diagnosed and Early-Stage Patients, Poorly Controlled and Therapy-Escalation Patients); By Care and Technology Layer (Drug Therapy, Continuous Glucose Monitoring-Supported Care, Automated Insulin Delivery-Supported Care, Connected Pens and Digital Titration Support); By Distribution and Access Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Programs and Institutional Procurement); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Type 2 Diabetes Mellitus Treatment Market: GLP-1 Scale, Organ-Protection Prescribing, and Weekly Insulin Reshape Chronic Metabolic Care

The Global Type 2 Diabetes Mellitus Treatment Market was valued at USD 58.2 billion in 2025 and is projected to reach USD 103.24 bil... Read More

Published Date: JUL-2026 | No Of Pages:184 | $ 4485

Urinary Incontinence Therapeutics Market By Drug Class (Anticholinergics, Beta-3 Adrenergic Agonists, Botulinum Toxin, Topical Estrogen Therapy, Others); By Disease Type (Stress Urinary Incontinence, Urge Urinary Incontinence/Overactive Bladder, Mixed Urinary Incontinence, Overflow Incontinence); By Route of Administration (Oral, Injectable, Topical); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032.

Urinary Incontinence Therapeutics Market: β3-Agonist Growth, Low Treatment Penetration and Neuromodulation Investment Reshape Continence Care

The Global Urinary Incontinence Therapeutics Market was valued at USD 4.24 billion in 2025<... Read More

Published Date: JUL-2026 | No Of Pages:198 | $ 4485

Ankylosing Spondylitis Market By Drug Class (TNF Inhibitors, Interleukin Inhibitors, JAK Inhibitors, NSAIDs & Conventional DMARDs); By Route of Administration (Parenteral, Oral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Ankylosing Spondylitis Market expands with CAGR 7.4%, starting at $6.9 billion in 2024 and reaching $10.6 billion by 2030, shaped by Read More

Published Date: OCT-2025 | No Of Pages:191 | $ 4485

Thyroid Gland Disorder Treatment Market By Treatment Type (Hormone Replacement Therapy, Antithyroid Medication, Radioactive Iodine Therapy, Surgery, Targeted Biologics); By Indication (Hypothyroidism, Hyperthyroidism, Thyroid Cancer, Other Disorders); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Statistical Snapshot — Global Thyroid Gland Disorder Treatment Market (2024-2030)

  • The Global Thyroid Gland Disorder Treatment Market is projected to grow at a 6.4% CAGR, expanding from USD 3.9 billion in 20... Read More

    Published Date: OCT-2025 | No Of Pages:179 | $ 4485

Castrate-Resistant Prostate Cancer Market By Therapy Type (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiopharmaceutical Therapy, Targeted Therapy); By Drug Class (Androgen Receptor Inhibitors, CYP17 Inhibitors, PARP Inhibitors, Cytotoxic Agents, Immune Checkpoint Inhibitors, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Castrate-Resistant Prostate Cancer (CRPC) Market will see steady momentum with CAGR 7.9%, starting at $10.2 billion in 2024 and climbing to $16.2 ... Read More

Published Date: OCT-2025 | No Of Pages:160 | $ 4485

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market By Drug Type (Monoclonal Antibodies, Recombinant Fusion Proteins, Small Molecule Inhibitors, Biosimilars); By Route of Administration (Intravitreal Injection, Intravenous Infusion, Oral); By Application (Ophthalmology [AMD, DME, RVO], Oncology [Colorectal Cancer, NSCLC, RCC, Others]); By End User (Hospitals, Specialty Clinics, ASCs, Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Anti-VEGF Therapeutics Market: Biosimilars Reprice the Injection Base as Durability Becomes the Premium Battleground

The Global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market is estimated to reach USD 14.23 billion in ... Read More

Published Date: JUL-2026 | No Of Pages:165 | $ 4485

Connective Tissue Disease Market By Disease Type (SLE, Systemic Sclerosis, Sjögren’s Syndrome, Polymyositis & Dermatomyositis, MCTD, Others); By Treatment Type (Immunosuppressants, Corticosteroids, NSAIDs, Biologics & Monoclonal Antibodies, DMARDs, Adjunctive Therapies); By Route of Administration (Oral, Intravenous, Subcutaneous, Topical); By End User (Hospitals, Specialty Clinics, Home Healthcare, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Connective Tissue Disease Market will witness a robust CAGR of 7.3%, valued at $6.12 billion in 2024 , and is expected to appreciate and reach $9.34 bill... Read More

Published Date: OCT-2025 | No Of Pages:200 | $ 4485

Breast Adenocarcinoma Treatment Market By Treatment Type (Surgery, Radiotherapy, Chemotherapy, Endocrine Therapy, Targeted Therapy, Immunotherapy, Antibody–Drug Conjugates), By Disease Stage (Early-Stage and Localized Breast Adenocarcinoma, Locally Advanced Breast Adenocarcinoma, Recurrent and Metastatic Breast Adenocarcinoma), By Molecular Subtype (Hormone Receptor-Positive/HER2-Negative, HER2-Positive, HER2-Low and HER2-Ultralow, Triple-Negative Breast Cancer), By End User (Hospitals, Cancer and Oncology Centers, Specialty Clinics, Ambulatory Surgical Centers), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Breast Adenocarcinoma Treatment Market: From Procedure-Led Curative Care to a Biomarker-Driven, Recurring Systemic Therapy Economy

The Global Breast Adenocarcinoma Treatment Market was valued at an estimated USD 36.10 billion in 2025 and is projected to reach USD 66.8... Read More

Published Date: AUG-2026 | No Of Pages:177 | $ 4485

Bipolar Disorder Treatment Market By Drug Class (Mood Stabilizers, Atypical Antipsychotics, Anticonvulsants, Antidepressants, Others); By Route of Administration (Oral, Parenteral, Transdermal); By End User (Hospitals, Outpatient Clinics, Private Practices, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Bipolar Disorder Treatment Market will witness steady expansion at a CAGR of 6.8%, rising from $7.4 billion in 2024 to $10.9 billion by 2030, supported by... Read More

Published Date: OCT-2025 | No Of Pages:182 | $ 4485

Lymphoma Treatment Market By Therapy Type (Chemotherapy and Chemoimmunotherapy, Monoclonal Antibodies, Targeted Therapy, Antibody-Drug Conjugates, Bispecific Antibodies, CAR-T Cell Therapy, Checkpoint Inhibitors, Stem Cell Transplantation); By Lymphoma Type (Non-Hodgkin Lymphoma, Hodgkin Lymphoma); By Treatment Line (First-Line Treatment, Second-Line Treatment, Third-Line and Later-Line Treatment, Relapsed/Refractory Treatment, Maintenance Treatment); By End User (Hospitals, Comprehensive Cancer Centers, Specialty Oncology Centers, Outpatient Oncology Centers, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Lymphoma Treatment Market: Earlier-Line Bispecific Approvals and Cell-Therapy Capacity Expand the Revenue Pool

The Global Lymphoma Treatment Market will witness strong growth at a CAGR of 9.3%, growing from USD 7.6 billion in 2025 to USD 14.16 billion by 2032, accordi... Read More

Published Date: JUL-2026 | No Of Pages:155 | $ 4485

Food Allergy Treatment Market By Treatment Type (Preventive Anti-IgE Biologics, Injectable Epinephrine Auto-Injectors, Intranasal Epinephrine, Peanut Oral Immunotherapy, Antihistamines, Corticosteroids, and Other Adjunctive Medicines); By Patient Group (Pediatric and Adult); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Specialty Pharmacies, and Online Pharmacies); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Food Allergy Treatment Market: Preventive Biologics and Needle-Free Epinephrine Reshape Commercial Demand

The Global Food Allergy Treatment Market was valued at USD 7.16 billion in 2025 and is projected to reach USD 12.5 billion by 2032, growing at a CAGR of 8.31%, ac... Read More

Published Date: JUL-2026 | No Of Pages:153 | $ 4485

Blastic Plasmacytoid Dendritic Cell Neoplasm Market By Treatment Type (Chemotherapy Regimens, Targeted Therapies, Immunotherapies); By Route of Administration (Intravenous, Subcutaneous); By End User (Hospitals and Oncology Centers, Specialty Clinics, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Blastic Plasmacytoid Dendritic Cell Neoplasm ( BPDCN ) Market will witness a robust CAGR of 8.7% , valued at USD... Read More

Published Date: OCT-2025 | No Of Pages:153 | $ 4485

Hunter Syndrome Treatment Market By Treatment Type Standard Enzyme Replacement Therapy, CNS-Directed Enzyme Replacement Therapy, Gene Therapy, Supportive and Symptom Management; By Disease Phenotype Neuronopathic Hunter Syndrome, Non-Neuronopathic Hunter Syndrome; By Diagnosis / Treatment Stage Presymptomatic / Newborn-Screened Pediatric Patients, Early Symptomatic Pediatric Patients, Advanced Neurologic Disease Patients, Long-Term Managed Patients; By Administration Model Weekly Intravenous Infusion, One-Time Gene Therapy Administration, Ex Vivo Stem-Cell Gene Therapy Administration, Supportive Care-Based Treatment; By End User Metabolic Specialty Centers, Hospitals, Pediatric Rare Disease Clinics, Home Infusion Providers; By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hunter Syndrome Treatment Market: CNS-Directed ERT, Newborn Screening, and Gene Therapy Redraw MPS II Care

The Global Hunter Syndrome Treatment Market will witness steady expansion at a CAGR of 6.4%, growing from USD 1.31 billion in 2025 to USD 2.02 billion by 2032, a... Read More

Published Date: JUL-2026 | No Of Pages:187 | $ 4485

Hepatitis Therapeutics Market By Drug Class (Direct-Acting Antivirals, Nucleos(t)ide Analogues, Immune Modulators, Combination Therapies); By Disease Type (Hepatitis B, Hepatitis C, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Hepatitis Therapeutics Market: Functional-Cure Innovation and Concentrated Country Burden Reshape Antiviral Demand

The Global Hepatitis Therapeutics Market is estimated to reach USD 18.58 billion in 2025 and is projected to grow to Read More

Published Date: JUL-2026 | No Of Pages:187 | $ 4485

Phenylketonuria (PKU) Treatment Market By Treatment Type (Medical Foods, Enzyme Replacement Therapy, Gene Therapy, Pharmacological Treatments); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online); By Region (North America, Europe, Asia Pacific, LAMEA), Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Phenylketonuria ( PKU ) Treatment Market will witness a robust CAGR of 6.5% , valued at $1.2 bi... Read More

Published Date: OCT-2025 | No Of Pages:183 | $ 4485

Lysosomal Acid Lipase Deficiency Treatment Market By Treatment Type (Enzyme Replacement Therapy, Supportive Care & Symptomatic Treatment, Gene Therapy, Combination Therapy, Investigational Therapies); By Disease Type (Later-Onset LAL Deficiency/Cholesteryl Ester Storage Disease, Infantile-Onset LAL Deficiency, Asymptomatic Adult LAL Deficiency); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals & Clinics, Specialty Care Centers, Academic & Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Diagnostic Identification and Lifelong Enzyme Therapy Define LAL-D Market Value – (Updated On: 16th-Sep-2026)

The Global Lysosomal Acid Lipase Deficiency Treatment Market was valued at USD 410 million in 2025 and is projected to reach USD 681 million by 203... Read More

Published Date: OCT-2025 | No Of Pages:180 | $ 4485

Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Treatment Type (Medication-Based Therapy, Gene and Cell Therapy, Symptomatic Treatment); By Route of Administration (Oral, Intravenous, Subcutaneous, Others); By End User (Hospitals, Specialized Neurology Clinics, Homecare Settings, Research and Academic Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market will witness steady expansion at a CAGR of 8.4%, rising from $1.26 billion in 2024 to $2.04 billion by 2030Read More

Published Date: OCT-2025 | No Of Pages:150 | $ 4485

Autoimmune Hemolytic Anemia (AIHA) Treatment Market By Treatment Type (Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Blood Transfusions, Surgical Interventions, Complement Inhibitors); By Route of Administration (Oral, Intravenous, Subcutaneous); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Autoimmune Hemolytic Anemia ( AIHA ) Treatment Market will witness a robust CAGR of 7.1% , valued at Read More

Published Date: OCT-2025 | No Of Pages:181 | $ 4485

Age-Related Macular Degeneration (AMD) Market By Disease Type (Wet AMD, Dry AMD); By Therapy Type (Anti-VEGF Agents, Complement Inhibitors, Nutritional Supplements, Gene Therapy, Photodynamic Therapy, Laser Photocoagulation, Others); By Route of Administration (Intravitreal, Oral, Subretinal, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Age-Related Macular Degeneration (AMD) Market - Wet AMD Remains the Revenue Core While Dry AMD Therapies Expand the Treatment Market

The Global Age-Related Macular Degeneration (AMD) Market was valued at USD 11.95 billion in 2025 and is projected to reach USD 20.22 bi... Read More

Published Date: AUG-2026 | No Of Pages:170 | $ 4485

Basal Cell Carcinoma Treatment Market By Treatment Type (Standard Surgical Excision, Mohs Micrographic Surgery, Curettage and Electrodessication, Cryosurgery, Topical Therapy, Photodynamic Therapy, Radiation Therapy, Systemic Therapy); By Disease Stage (Localized Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma); By End User (Dermatology Clinics and Mohs Centers, Hospitals and Cancer Centers, Ambulatory Surgical Centers, Radiation Therapy Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Basal Cell Carcinoma Treatment Market: Rising Lesion Volumes Keep Surgery at the Center of Care

The Global Basal Cell Carcinoma Treatment Market was valued at USD 3.46 billion in 2025 and is projected to reach USD 6.37 billion by 2032, growing at a CAGR of 9.1%, accor... Read More

Published Date: JUL-2026 | No Of Pages:151 | $ 4485

Metabolic Disorder Therapeutics Market By Product Type (Insulin and Insulin Analogs, Enzyme Replacement Therapies, Gene Therapies, RNA-Based Therapeutics, Small Molecule Drugs, Other Biologics); By Application (Diabetes Mellitus, Obesity, Lysosomal Storage Disorders, Hypercholesterolemia and Dyslipidemia, Other Metabolic Disorders); By End User (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies, Research & Academic Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Metabolic Disorder Therapeutics Market will witness a robust CAGR of 7.4% , valued at USD 72.6 billion in 2024 , expected to appreciate and reach USD 112.5 billion... Read More

Published Date: OCT-2025 | No Of Pages:156 | $ 4485

Allergy Immunotherapy Market By Treatment Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy); By Allergy Type (Allergic Rhinitis, Asthma, Venom Allergy, Food Allergy, Others); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Allergy Immunotherapy Market: Prescription Tablets, Pediatric Expansion, and Long-Term Treatment Economics Reshape Allergy Care

The Global Allergy Immunotherapy Market is estimated to reach USD 2.77 billion in 2025 and is projected to... Read More

Published Date: JUL-2026 | No Of Pages:154 | $ 4485

Osteoarthritis Therapeutics Market By Drug Class (NSAIDs, Corticosteroids, Viscosupplements, Biologics, DMOADs); By Route of Administration (Oral, Topical, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Osteoarthritis Therapeutics Market is projected to grow at a robust CAGR of 9.3 % , reaching an estimated value of $ 16.42Read More

Published Date: OCT-2025 | No Of Pages:153 | $ 4485

Non-Alcoholic Steatohepatitis (NASH) Treatment Market By Drug Class (THR-β Agonists, GLP-1 Receptor Agonists, Dual Incretin Therapies, FGF21 Analogues, PPAR Agonists, Glucagon/GLP-1 Dual Agonists, Supportive Metabolic Therapies); By Disease Stage (Noncirrhotic MASH/NASH with F2 Fibrosis, Noncirrhotic MASH/NASH with F3 Fibrosis, Compensated Cirrhosis, High-Risk MASLD Patients Under Evaluation); By Route of Administration (Oral Therapies, Injectable Therapies); By Treatment Setting (Hepatology Clinics, Gastroenterology Clinics, Endocrinology & Diabetes Clinics, Obesity & Weight-Management Centers, Hospitals, Specialty Liver Centers); By Patient Risk Group (Patients with Type 2 Diabetes, Patients with Obesity, Patients with Moderate-to-Advanced Fibrosis, Patients with Cardiometabolic Risk, Patients Referred Through Abnormal Liver Tests); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Non-Alcoholic Steatohepatitis Treatment Market: Fibrosis-Defined Approvals, GLP-1 Competition, and Testing Capacity Redraw MASH Care

The Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market was valued at USD 8.75 billion in 2025 and is projected to reach USD 4... Read More

Published Date: JUL-2026 | No Of Pages:175 | $ 4485

Catastrophic Antiphospholipid Syndrome Market By Treatment Modality (Plasma Exchange, Anticoagulation Therapy, Immunosuppressive Agents, Intravenous Immunoglobulins, Complement Inhibitors); By Diagnostic Approach (ELISA, Lupus Anticoagulant Testing, Beta-2 Glycoprotein I Testing, Next-Generation Sequencing); By End User (Hospitals & Critical Care Centers, Specialty Clinics & Immunology Centers, Academic & Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Catastrophic Antiphospholipid Syndrome ( CAPS ) Market will witness a robust CAGR of 7.4% , valued at $654 million in 2024Read More

Published Date: OCT-2025 | No Of Pages:153 | $ 4485

Rheumatoid Arthritis Therapeutics Market By Drug Class (Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs, NSAIDs, Corticosteroids); By Route of Administration (Oral, Parenteral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Rheumatoid Arthritis Therapeutics Market is set to expand at a robust CAGR of 6.8%, valued at $28.4 billion in 2024 and projected to reach $42.1 billion by 2030Read More

Published Date: OCT-2025 | No Of Pages:183 | $ 4485

Guillain-Barre Syndrome Market By Treatment Type (IVIG, Plasmapheresis, Steroid Therapy, Supportive Care); By Route of Administration (Intravenous, Oral, Subcutaneous); By End User (Hospitals, Neurology Clinics, ASCs, Rehabilitation Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Guillain - Barré Syndrome ( GBS ) Market will witness a robust CAGR of ... Read More

Published Date: OCT-2025 | No Of Pages:186 | $ 4485

Huntingtons Disease Treatment Market By Treatment Type (Symptomatic Treatment, Disease-Modifying Therapies); By Route of Administration (Oral, Injectable, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Huntington’s Disease Treatment Market is projected to appreciate at a strong CAGR of 21.1%, valued at $1.3 billion in 2024 and forecast to reach $3.9 billion... Read More

Published Date: OCT-2025 | No Of Pages:171 | $ 4485

Endometriosis Treatment Market By Treatment Type (Hormonal Therapy, Pain Management, Surgery); By Route of Administration (Oral, Injectable, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Endometriosis Treatment Market will witness a robust CAGR of 7.6%, valued at USD 2.45 billion in 2024 and expected to appreciate and reach USD 3.82 billion by 2030... Read More

Published Date: OCT-2025 | No Of Pages:170 | $ 4485

Acromegaly Treatment Market By Treatment Modality (Pituitary Surgery, Somatostatin Receptor Ligands, Growth Hormone Receptor Antagonists, Dopamine Agonists, Radiation Therapy, Combination Therapy); By Drug Class (Octreotide, Lanreotide, Paltusotine, Pegvisomant, Pasireotide, Cabergoline, Other Therapies); By Route of Administration & Delivery Format (Oral Therapies, Clinic-Administered Injectables, Self-Injected Depots, Daily Subcutaneous Injections); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Specialty Distributors, Retail Pharmacies); By End User (Hospitals, Pituitary Centers, Endocrinology Clinics, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Acromegaly Treatment Market: Palsonify Launch, Self-Injected Depots, and Post-Surgical Drug Demand Reshape Competition

The Global Acromegaly Treatment Market was valued at USD 1.74 billion in 2025 and is projected to reach USD 2.69 billion by 2032, growing at a CAGR o... Read More

Published Date: JUL-2026 | No Of Pages:182 | $ 4485

Acute Repetitive Seizures Market By Product Type (Intranasal Rescue Therapies, Buccal and Sublingual Formulations, Injectable Rescue Medications); By Route of Administration (Nasal, Oral/Buccal, Intramuscular/Intravenous); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Acute Repetitive Seizures Market is projected at 13.1% CAGR, starting at $805 million (2024) and advancing to $1.67 billion (2030), with traction in Read More

Published Date: OCT-2025 | No Of Pages:181 | $ 4485

Postmenopausal Osteoporosis Treatment Market By Treatment Class (Bisphosphonates, RANK Ligand Inhibitors [Denosumab and Biosimilars], Parathyroid Hormone Analogs [Teriparatide and Abaloparatide], Sclerostin Inhibitors [Romosozumab], Selective Estrogen Receptor Modulators [SERMs], Menopausal Hormone Therapy, Calcitonin, Calcium and Vitamin D Supplements, Others); By Route of Administration (Oral, Subcutaneous, Intravenous, Intranasal, Transdermal, Others); By Patient Risk Group (Osteopenia with Elevated Fracture Risk, High-Risk Osteoporosis, Very-High-Risk or Severe Osteoporosis, Post-Fracture Secondary Prevention); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Specialty Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Postmenopausal Osteoporosis Treatment Market: Treatment Sequencing, Access Gaps, and Competitive Change

Fracture Risk Defines the Commercial and Clinical Burden

The Global Postmenopausal Osteoporosis Treatment Market was valued at USD 1... Read More

Published Date: Aug-2026 | No Of Pages:183 | $ 4485

Pneumonia Therapeutics Market By Drug Class (Antibiotics, Antivirals, Antifungals, Monoclonal Antibodies, Adjunct Therapies); By Etiology (Bacterial, Viral, Fungal, Aspiration, Atypical); By Route of Administration (Oral, Intravenous, Inhalation); By End User (Hospitals, Specialty Clinics, Retail Pharmacies, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Pneumonia Therapeutics Market is on track for 6.4% CAGR, increasing from $17.3 billion in 2024 to $25.2 billion by 2030, shaped by vaccinesRead More

Published Date: OCT-2025 | No Of Pages:168 | $ 4485

Insomnia Therapeutics Market By Treatment Type (Prescription Medications [Non-benzodiazepine Hypnotics, Benzodiazepines, Melatonin Receptor Agonists, Orexin Receptor Antagonists], Over-the-Counter Sleep Aids, Digital and Behavioral Therapeutics); By Route of Administration (Oral, Transdermal, Others); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Platforms); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Insomnia Therapeutics Market climbs at CAGR of 6.8%, starting at $4.9 billion in 2024 and reaching $7.3 billion by 2030,... Read More

Published Date: OCT-2025 | No Of Pages:175 | $ 4485

Actinic Keratosis Treatment Market By Treatment Type (Topical Medications, Cryotherapy, Photodynamic Therapy, Laser Therapy, Others); By End User (Hospitals and Dermatology Clinics, Ambulatory Surgical Centers, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Actinic Keratosis Treatment Market will witness a robust CAGR of 6.8%, valued at $7.2 billion in 2024, and is expected to reach $10.7 billion by 2... Read More

Published Date: OCT-2025 | No Of Pages:176 | $ 4485

Paroxysmal Nocturnal Hemoglobinuria Market By Drug Type (C5 Inhibitors, C3 Inhibitors, Others); By Route of Administration (Intravenous, Subcutaneous, Oral); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies); By End User (Hospitals, Specialty Clinics, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market will witness a robust CAGR of 9.7 % ,... Read More

Published Date: OCT-2025 | No Of Pages:166 | $ 4485

Hemophilia Treatment Market By Product Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factors, Non-Factor Replacement Therapies, Gene Therapy); By Disease Type (Hemophilia A, Hemophilia B, Others); By Treatment Approach (On-Demand Therapy, Prophylactic Therapy, Immune Tolerance Induction Therapy); By End User (Hospitals & Hemophilia Treatment Centers, Home Care Settings, Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Hemophilia Treatment Market expected to grow to $17.31 billion by 2030 from $10.45 billion in 2024 at a CAGR of 8.78%, propelled by deman... Read More

Published Date: OCT-2025 | No Of Pages:160 | $ 4485

Dementia Treatment Market By Product Type (Symptomatic Treatments [Cholinesterase Inhibitors, NMDA Receptor Antagonists, Other Symptomatic Medicines], Disease-Modifying Treatments [Anti-Amyloid Monoclonal Antibodies, Other Disease-Modifying Therapies]); By Application (Alzheimer’s Disease, Vascular Dementia, Dementia with Lewy Bodies, Frontotemporal Dementia, Mixed Dementia, Other Dementia Types); By End User (Hospitals, Neurology and Memory Clinics, Infusion Centers, Retail Pharmacies, Online Pharmacies, Home-Care Settings); By Route of Administration (Oral, Intravenous, Subcutaneous, Transdermal); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Dementia Treatment Market: Early Diagnosis, Reimbursement, and Easier Drug Delivery Shift Revenue Toward Disease-Modifying Care

The Global Dementia Treatment Market was valued at USD 11.79 billion in 2025 and is projected to reach USD 27.42 billion by 2032, growing at... Read More

Published Date: JUL-2026 | No Of Pages:165 | $ 4485

Anxiety Disorder Treatment Market By Treatment Type (Pharmacotherapy, Psychotherapy, Digital and Hybrid Therapy, and Medication Management and Follow-Up Care); By Disorder Type (Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Specific Phobias, Agoraphobia, Separation Anxiety Disorder, Selective Mutism, and Other Anxiety Disorders); By Care Delivery Setting (Primary Care Practices, Psychiatry Practices, Behavioral Health and Therapy Clinics, Hospitals and Public Mental-Health Services, Telehealth and Digital Platforms, and Pediatric and School-Linked Services); By Patient Group (Adults, Adolescents and Young Adults, Pediatric Patients, Women-Focused Anxiety Care, and Geriatric Patients); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Anxiety Disorder Treatment Market: Low Treatment Access, Therapy Capacity Constraints, and Drug Discontinuation Reshape Care Delivery

The Global Anxiety Disorder Treatment Market was valued at USD 13.84 billion in 2025 and is projected to reach USD 19.13 billion by 20... Read More

Published Date: JUL-2026 | No Of Pages:172 | $ 4485

Myeloproliferative Disorder Treatment Market By Disorder Type (PV, ET, PMF); By Treatment (JAK Inhibitors, Chemotherapy, Stem Cell Transplantation); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital, Retail, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Myeloproliferative Disorder Treatment Market is expected to witness a steady CAGR of 6.9% , valued at $5.4 billion in 2024 , and projected to reach $8.1 billion by... Read More

Published Date: OCT-2025 | No Of Pages:151 | $ 4485

Pancreatic Cancer Treatment Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiotherapy, Others); By Disease Stage (Localized, Locally Advanced, Metastatic); By End User (Hospitals & Cancer Centers, Specialty Clinics, Research & Academic Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Pancreatic Cancer Treatment Market will witness a robust CAGR of 11.8% , valued at USD 6.4 billion in 2024 , expected to appreciate and r... Read More

Published Date: OCT-2025 | No Of Pages:158 | $ 4485

Anterior Uveitis Treatment Market By Treatment Type (Topical Corticosteroids, Cycloplegic Agents, Topical Nonsteroidal Anti-Inflammatory Drugs, Periocular Corticosteroid Injections, Systemic Corticosteroids, Conventional Immunomodulators, Biologic Therapies, Steroid-Free Topical Immunomodulators); By Disease Etiology (Noninfectious Anterior Uveitis, Infectious Anterior Uveitis, Autoimmune/Systemic Disease-Associated Anterior Uveitis, Juvenile Idiopathic Arthritis-Associated Anterior Uveitis); By Treatment Intensity (Acute Episodic Treatment, Recurrent Disease Management, Severe or Steroid-Dependent Disease Management, Complication-Associated Treatment); By Patient Group (Adults, Pediatrics); By Distribution Channel (Retail Pharmacies and Drug Stores, Hospital Pharmacies, Specialty Pharmacies, Online and Mail-Order Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Anterior Uveitis Treatment Market: Steroid-Free Topical Therapies Target Recurrent and Pressure-Sensitive Disease

The Global Anterior Uveitis Treatment Market was valued at USD 476.5 million in 2025 and is projected to reach USD 850 million by 2032, growing at a CAGR ... Read More

Published Date: JUL-2026 | No Of Pages:159 | $ 4485

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Gastroesophageal Reflux Disease Therapeutics Market By Drug Class (PPIs, H2 Receptor Antagonists, Antacids, Prokinetics, Mucosal Protectants); By Route of Administration (Oral, Intravenous); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Gastroesophageal Reflux Disease Therapeutics Market: P-CAB Adoption Raises Acid-Control Value

The Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market is estimated to reach USD 7.82 billion in 2025 and is projected to gro... Read More

Published Date: JUL-2026 | No Of Pages:171 | $ 4485

Inflammatory Bowel Disease (IBD) Treatment Market By Drug Class (Biologics [TNF-alpha Inhibitors, Integrin Inhibitors, Interleukin Inhibitors], Small Molecules [JAK Inhibitors, S1P Receptor Modulators], 5-ASA Derivatives, Corticosteroids, Immunomodulators, Others); By Disease Type (Crohn’s Disease, Ulcerative Colitis); By Route of Administration (Oral, Injectable, Rectal); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Inflammatory Bowel Disease (IBD) Treatment Market is forecast to expand from $24.8 billion in 2024 to $37.1 billion by 2030 at a 6.9% CAGR, supported by r... Read More

Published Date: OCT-2025 | No Of Pages:187 | $ 4485

Metastatic Lung Adenocarcinoma Treatment Market By Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy, Radiotherapy, Combination Therapy); By Biomarker Status (EGFR Mutation, ALK Rearrangement, KRAS Mutation, PD-L1 Expression, Wild-Type); By Route of Administration (Oral, Intravenous, Subcutaneous); By End User (Hospitals, Specialty Clinics, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Metastatic Lung Adenocarcinoma Treatment Market will increase from $12.4 billion in 2024 to $23.1 billion by 2030 at a 9.2% CAGR, supported by advancement... Read More

Published Date: OCT-2025 | No Of Pages:193 | $ 4485

Neuroendocrine Tumor Treatment Market By Treatment Type (Somatostatin Analogues, Peptide Receptor Radionuclide Therapy, Targeted Therapies, Chemotherapy, Liver-Directed Therapies, Oral Somatostatin-Pathway Therapies, Other Treatments); By Tumor Type (Gastroenteropancreatic NETs, Pancreatic NETs, Extra-Pancreatic NETs, Lung NETs, Poorly Differentiated Neuroendocrine Carcinomas, Others); By SSTR Status (SSTR-Positive NETs, SSTR-Negative NETs); By End User (Hospitals, Specialty Oncology Centers, Nuclear Medicine Centers, Academic & Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Neuroendocrine Tumor Treatment Market: PRRT Expansion, Cabozantinib Approval, and SSTR Imaging Redraw Long-Term NET Care

The Global Neuroendocrine Tumor (NET) Treatment Market was valued at USD 2.59 billion in 2025 and is projected to reach USD 4.12 billion by 2032, r... Read More

Published Date: JUL-2026 | No Of Pages:160 | $ 4485

Transthyretin Amyloidosis Treatment Market By Drug Type (RNA Interference, Antisense Oligonucleotides, TTR Stabilizers, Supportive Therapies); By Route of Administration (Intravenous, Oral, Others); By End User (Hospitals & Specialty Clinics, Outpatient & Home Care, Research Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Transthyretin Amyloidosis Treatment Market will witness a robust CAGR of 13.8%, valued at USD 2.1 billion in 2024, expected to appreciate... Read More

Published Date: OCT-2025 | No Of Pages:168 | $ 4485

Infectious Disease Therapeutics Market By Product Type (Antiviral Drugs, Antibacterial Drugs, Antifungal and Antiparasitic Drugs, Monoclonal Antibodies and Immunotherapies); By Indication (HIV/AIDS, Hepatitis, Influenza, Tuberculosis, Malaria, Others); By Route of Administration (Oral, Parenteral, Topical); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Infectious Disease Therapeutics Market is projected at 7.4% CAGR, rising from $145.6 billion in 2024 to $322.5 billion by 2030, supported by biolo... Read More

Published Date: OCT-2025 | No Of Pages:156 | $ 4485